Polyrizon Ltd. PLRZ 深 沪
等待开盘 02-07 09:30:00 美东时间
12.845
+0.415
+3.34%
华盛通- 最 高13.67
- 今 开12.52
- 成交量 6.80万股
- 最 低 12.27
- 昨 收 12.43
- 总市值 1338.03万
- 52周最高 2235.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.88
- 委 比 -84.00%
- 总股本 104.17万
- 历史最高 7200.00
- 量 比 0.52
- 振 幅 11.26%
- 历史最低 4.80
- 每 手 1
- 风险率 479.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI
Polyrizon Ltd. ( ($PLRZ) ) has shared an update. On February 6, 2026, Polyrizon...
02-06 21:23
Polyrizon Intends To Acquire 51% Stake In Arrow Aviation Through Cash Investment Of ~$5.8M, Marking A Strategic Expansion Into Private Aviation Sector
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDARaanana,
02-04 20:16
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers AstraZeneca PLC Ordinary Shares (NYSE:AZN) stock rose 107.1% to $192.1...
02-03 01:05
Polyrizon Starts Key Usability Study Program For Its NASARIX Product Candidate
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study
01-22 22:29
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Polyrizon Ltd. has initiated a key usability study program for its lead product, NASARIX™, an intranasal allergy blocker. The study, conducted in compliance with FDA human factors and usability engineering guidelines, aims to ensure alignment with regulatory requirements and support a smoother path to clinical development. Successful completion will provide critical evidence for NASARIX™ readiness for clinical evaluation, with clinical trials exp...
01-22 14:25
Polyrizon Completes Branding Of PL-14 Allergy Blocker As NASARIX, Advancing Commercial Readiness
As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European marketsRaanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd.
01-08 21:47
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
Polyrizon Ltd. announced the completion of its branding process for the allergy blocker PL-14, naming it NASARIX™. Based on the company's proprietary Capture and Contain™ hydrogel technology, NASARIX™ is designed as an innovative intranasal spray to create a protective barrier against allergens and viruses. The brand name was selected following comprehensive trademark screening and linguistic evaluations in U.S. and European markets. Polyrizon ai...
01-08 13:45
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of GH Research PLC (NASDAQ:GHRS) rose sharply in pre-market trading afte...
01-05 17:27
Polyrizon Explores Revenue-Generating Asset Investments While Advancing Core Biotech Pipeline
Polyrizon Ltd. Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided
2025-12-29 20:21
Polyrizon Submits Pre-RFD To FDA For Its PL-16 Viral Blocker Designed To Reduce Exposure To Influenza And Cold Viruses
The PL-16 Viral Blocker has shown over 90% success in protection of cells against virusesRaanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal
2025-12-19 21:23
